Cable Viewer

Currently released so far... 12532 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04 2011/05/05 2011/05/06 2011/05/07 2011/05/08 2011/05/09 2011/05/10 2011/05/11

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/06 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown Consulate Fukuoka
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy Niamey Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sapporo Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ASEC AF AR ARF AG AORC APER AS AU AJ AM ABLD APCS AID APECO AMGT AFFAIRS AMED AFIN ADANA AEMR AE ADCO AA AECL AADP ACAO ANET AY APEC AORG ASEAN ABUD AINF AFSI AFSN AGR AROC AO AODE AL ACABQ AGMT AORL AX AMEX ATRN ADM AFGHANISTAN AZ ASUP AND ARM AQ ATFN AMBASSADOR ACBAQ ADPM AC ASIG ASCH AGAO ACOA AUC ASEX AIT AMCHAMS AER AVERY AGRICULTURE AMG AFU AN ALOW ASECKFRDCVISKIRFPHUMSMIGEG ACS
BA BR BU BK BEXP BO BL BM BC BT BRUSSELS BX BIDEN BTIO BG BE BD BY BBSR BB BP BN BILAT BF BH BTIU BWC BMGT
CO CH CA CS CE CASC CU CI CDG CVIS CG CWC CIDA CM CICTE CMGT COUNTER CPAS COUNTRY CJAN CBW CBSA CEUDA CD CAC CODEL CW CBE CHR CT CDC CFED COM CIS CR CKGR CVR CIA CLINTON CY COUNTERTERRORISM CITEL CLEARANCE COE CN CARICOM CB CONDOLEEZZA CACS CSW CIC CITT CONS COPUOS CL CARSON CACM CDB CROS CLMT CTR CJUS CF CTM CAN CAPC CV CBC CNARC
DR DA DK DJ DHS DPRK DEPT DEA DISENGAGEMENT DE DOMESTIC DOD DOE DS DTRA DEFENSE DO DAO DCM DEAX
ETTC EFIN ECON EAIR EG EINV ETRD ENRG EC EFIS EAGR EUN EAID ELAB ER EPET EMIN EU ECPS EN EWWT ELN EIND ELTN EINT ECA EPA ENGR ETRC EXTERNAL ELECTIONS EZ ECIN EI ENVI ETRO ETRDEINVECINPGOVCS ETRN ET EK ES EINVEFIN ERD EUR ETC ENVR EAP ENIV ECONOMY EINN EFTA ECONOMIC EXBS ECUN ENGY ECONOMICS EIAR EINDETRD EREL EUC ESENV ECONEFIN EURN EDU ETRDEINVTINTCS ECIP ENERG EFIM EAIDS EAIG ECONCS EEPET ESA EXIM ENNP ECINECONCS EFINECONCS EUREM ETRDECONWTOCS EUNCH EINVETC EINVECONSENVCSJA EUMEM ETRA ERNG
FI FR FTA FARC FJ FTAA FAC FOREIGN FBI FAO FAS FM FINR FREEDOM FOR FINANCE FOI FMLN FDA FO FISO
GV GG GM GH GOV GOI GL GT GY GAERC GA GF GR GE GZ GAZA GANGS GCC GTIP GERARD GLOBAL GTMO
HR HA HO HU HUMAN HK HILLARY HI HURI HSTC HYMPSK HUMOR HEBRON
IR IC IN IAEA IT IBRD IS ITU ILO IZ ID ICRC IPR ISRAELI IIP ICAO IMO INMARSAT IWC INTERNAL IV INDO ITPHUM ITPGOV ITALIAN IO IBET INR ICJ ICTY IRS IA INTERPOL IRAQI IEA INRB IL IMF ITRA ISLAMISTS ITALY IQ IAHRC IZPREL IRAJ IDP ILC IRC IACI IDA ITF IF ISRAEL ICTR IGAD INRA INRO IEFIN INTELSAT
JA JUS JO JM JP JOSEPH JAMES JOHNNIE JOHN
KCRM KJUS KWMN KISL KIRF KDEM KTFN KTIP KFRD KPRV KCOR KNNP KAWC KUNR KGHG KV KIPR KFLU KSTH KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KSUM KTIA KTDB KPAO KMPI KZ KMIG KBCT KSCA KN KPKO KPAL KIDE KOMC KS KOLY KU KWBG KPAONZ KNUC KHLS KMDR KE KNNPMNUC KSTC KWAC KERG KACT KSCI KHDP KDRG KVPR KICC KPRP KBIO KFLO KCFE KCIP KTLA KTEX KSEP KHIV KCSY KTRD KID KGIC KRVC KNAR KSPR KMRS KNPP KJUST KMCA KPWR KG KTER KRCM KIRC KR KSEO KNEI KTBT KCFC KSAF KSAC KCHG KAWK KGCC KPLS KREL KMFO KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KFTFN KVRP KBTR KCOM KO KLIG KDEMAF KRAD KOCI KAID KNSD KGIT KFSC KWMM KPAI KICA KHUM KREC KRIM KSEC KCMR KPIN KESS KDEV KCGC KOM KRGY KPOA KBTS KHSA KMOC KCRS KVIR KX KWWMN KPAK KWNM KWMNCS KRFD KDDG KIFR KFIN KOMS KCRCM KNUP
LE LY LI LG LH LTTE LU LO LAB LOG LA LT LABOR
MARR MU MOPS MNUC MO MASS MCAP MX MY MZ MUCN MTCRE MIL ML MEDIA MPOS MA MP MERCOSUR MG MR MI MD MK MOPPS MASC MTS MLS MILI MAR MEPN MAPP MTCR MEPI MEETINGS MW MAS MRCRE MT MCC MIK MAPS MARAD MDC MQADHAFI MTRE MV MEPP MILITARY MASSMNUC MC
NZ NL NATO NO NI NU NS NASA NAFTA NP NDP NIPP NPT NG NEW NE NSF NZUS NR NH NA NSG NC NRR NATIONAL NT NGO NSC NPA NV NK NAR NORAD NSSP NATOPREL NW NPG NSFO
OVIP OPDC OTRA OREP OAS OPRC OPIC OECD OPCW OFDP OIIP OEXC ODIP OSCE OBSP OSCI OIE OTR OMIG OSAC OFFICIALS ON OFDA OES OVP OCII OHUM OPAD OIC OCS
PREL PGOV PHUM PINR PTER PARM PREF PK PINS PMIL PA PE PHSA PM PROP PALESTINIAN PBTS PARMS POL PO PROG PL PAK POLITICS PBIO PTBS POLICY PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PTERE PRGOV PORG PP PS PGOF PKFK PSOE PEPR PPA PINT PMAR PRELP PREFA PINF PNG PFOR PUNE PDOV PGOVLO PAO PHUMBA PSEPC PCUL PNAT PREO PLN PNR POLINT PRL PGOC POGOV PU PF PY PGOVE PG PCI PINL POV PAHO PGGV PHALANAGE PARTY PHUS PDEM PECON PROV PAS PHUMPREL PGIV PRAM PHUH PSA PHUMPGOV PEL PSI PAIGH POLITICAL PARTIES POSTS
QA
RU RS RP REACTION REPORT RIGHTS RO RCMP RW RM REGION RSP RF RICE RFE RUPREL ROOD RIGHTSPOLMIL ROBERT RELATIONS RSO
SNAR SOCI SZ SENV SU SA SCUL SP SMIG SW SO SY SL SENVKGHG SR SF SYRIA SI SWE SARS SC SAN SN STEINBERG SG ST SPCE SIPDIS SYR SNARIZ SNARN SSA SHI SK SPCVIS SOFA SEVN SIPRS SNARCS SAARC SHUM SANC SEN SH SCRS
TRGY TBIO TU TS TSPA TSPL TT TPHY TK TI TERRORISM TH TIP TC TZ TNGD TW THPY TL TV TX TO TRSY TINT TN TURKEY TBID TD TF TFIN TP TAGS TR
UV UK UNGA US UY USTR UNSC UN UNHRC UP UG USUN UNEP UNESCO USPS UZ USEU UNCHR USAID UNMIK UNHCR UE UNVIE UAE UNO USOAS UNODC UNCHS UNFICYP UNIDROIT UNDESCO UNCHC UNDP UNAUS UNPUOS UNC UNCND UNICEF UNCSD UNDC USNC
VT VE VZ VTPREL VI VM VN VTIZ VAT VC VTEG
WTO WTRO WS WTRQ WI WZ WHO WWARD WBG WB WHA WITH WMD WIPO WMO WFP WHTI WEU WA
XG XT XZ XM XR XA XY XX XF XL XW XV XB XU XS XH XK XD XI XC XE XQ XTAG
YM YI YE YMCS
ZR ZB ZI ZU ZJ ZEALAND ZK ZF ZP ZN ZL ZA ZANU ZO ZOELLICK

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:57 | 2011-04-28 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`